These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 3515699)

  • 1. Cyclosporine therapy and other adjuncts in the perioperative period with cadaveric and living related donor kidney transplantation.
    Milgrom M; Esquenazi V; Olson L; Fuller L; Roth D; Condie R; Kyriakides G; Miller J
    Transplant Proc; 1986 Apr; 18(2 Suppl 1):8-11. PubMed ID: 3515699
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term results in cadaveric renal transplantation under cyclosporine therapy.
    Land W; Schneeberger H; Schleibner S; Illner WD; Abendroth D; Hillebrand G; Gokel JM; Albert E; Fornara P
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1244-6. PubMed ID: 1989200
    [No Abstract]   [Full Text] [Related]  

  • 3. Annual trends and triple therapy--1991-2000.
    Nishikawa K; Terasaki PI
    Clin Transpl; 2001; ():247-69. PubMed ID: 12211788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Japanese trial of cyclosporine in living related and cadaveric renal transplantation.
    Ochiai T; Toma H; Oka T; Takagi H; Kashiwabara H; Ishibashi M; Fukao K; Ota K; Hashimoto I; Sonoda T
    Transplant Proc; 1985 Aug; 17(4):2035-40. PubMed ID: 3895651
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognostic factors affecting graft and patient survival in cadaveric and living kidney transplantation.
    Kim SJ; Lee HH; Lee DS; Lee KW; Joh JW; Woo DH; Kwon GY; Oh HY; Kim YG; Huh WS; Kim DJ; Kim GS; Lee SK; Lee BB
    Transplant Proc; 2004 Sep; 36(7):2038-9. PubMed ID: 15518737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for cadaveric donor allograft survival in cyclosporine-prednisone-treated recipients.
    Kahan BD; Mickey R; Flechner SM; Lorber MI; Wideman CA; Kerman RH; Terasaki P; Van Buren CT
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1835-8. PubMed ID: 3547890
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of cyclosporine A in cadaver donor retransplants: a surprising effect of the sex of the donor.
    Cecka JM; Cicciarelli J; Terasaki PI
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1842-4. PubMed ID: 3274440
    [No Abstract]   [Full Text] [Related]  

  • 8. Significance of delayed function in cyclosporine-treated cadaver kidney transplants.
    Belitsky P; MacDonald AS; Gajewski J; Boudreau J; Bitter-Suermann H; Cohen A
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2096-9. PubMed ID: 3547912
    [No Abstract]   [Full Text] [Related]  

  • 9. Trial of cyclosporine vs OG37-325 in cadaveric renal transplantation: a preliminary report.
    Henry ML; Tesi RJ; Elkhammas EA; Ferguson RM
    Transplant Proc; 1993 Feb; 25(1 Pt 1):689-90. PubMed ID: 8438438
    [No Abstract]   [Full Text] [Related]  

  • 10. Transplantation of kidneys from living related donors. Comparison with cadaveric kidney transplantation.
    Thomson NM; Atkins RC; Scott DF; Marshall VC; McGinley E; Holdsworth SR; Ironside W
    Med J Aust; 1983 Dec 10-24; 2(12):609-12. PubMed ID: 6366497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The fate of living related donor kidney recipients after conversion from cyclosporine to azathioprine.
    Oka T; Omori Y; Aikawa I; Yasumura T; Nakai I; Matsui S
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2012-6. PubMed ID: 3547905
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of cyclosporine and Minnesota antilymphoblast globulin in the early postoperative treatment of primary cadaveric renal transplant recipients.
    Kupin W; Venkat KK; Oh HK; Dienst S; Levin NW
    Transplant Proc; 1987 Feb; 19(1 Pt 3):1882-5. PubMed ID: 3547893
    [No Abstract]   [Full Text] [Related]  

  • 13. Cyclosporine immunosuppression in cadaver kidney recipients with a remote positive crossmatch to the current donor.
    Belitsky P
    Transplant Proc; 1985 Aug; 17(4):1937-9. PubMed ID: 3895633
    [No Abstract]   [Full Text] [Related]  

  • 14. Perioperative cyclosporine: interaction with multifactorial variables and effect on allograft function.
    Mendez R; Koussa N; Alanizi A; Mendez RG; Iwaki Y; Bogaard TP; Khetan U
    Transplant Proc; 1986 Apr; 18(2 Suppl 1):12-5. PubMed ID: 3515677
    [No Abstract]   [Full Text] [Related]  

  • 15. Renal transplantation in cyclosporine-treated recipients at the Singapore General Hospital.
    Vathsala A; Woo KT
    Clin Transpl; 1999; ():189-97. PubMed ID: 11038637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable outcome of renal transplantation in patients with IgA nephropathy.
    Andresdottir MB; Hoitsma AJ; Assmann KJ; Wetzels JF
    Clin Nephrol; 2001 Oct; 56(4):279-88. PubMed ID: 11680657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kidney transplantation from living unrelated donors.
    Alfani D; Pretagostini R; Bruzzone P; Smits J; Persijn G; Cortesini R
    Clin Transpl; 1998; ():205-12. PubMed ID: 10503099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The intake of initially high doses of cyclosporine A in cadaveric kidney transplantation is not justified. Results of a prospective study.
    Niebel W; Albrecht KH; Metz K; Jakubowski HD; Windeck R; Eigler FW
    Transplant Proc; 1988 Feb; 20(1 Suppl 1):394-7. PubMed ID: 3279628
    [No Abstract]   [Full Text] [Related]  

  • 19. Cyclosporine use in early graft dysfunction.
    Gonwa TA; Nghiem DD; Schulak JA; Corry RJ
    Transplant Proc; 1986 Apr; 18(2 Suppl 1):104-12. PubMed ID: 3515675
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful long-term outcome with 0-haplotype-matched living-related kidney donors.
    Jones JW; Gillingham KJ; Sutherland DE; Payne WD; Dunn DL; Gores PF; Gruessner RW; Najarian JS; Matas AJ
    Transplantation; 1994 Feb; 57(4):512-5. PubMed ID: 8116034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.